Business
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational e
About this update from Viva Biotech Holdings
[{"type":"text","content":"Financial HighlightsRevenue reached RMB1,729.4 millionGross profit amounted to RMB655.6 millionGross profit margin recorded 37.9%, a YOY increase of 3.3 ppNet profit recorded RMB269.3 million, a YOY increase 21.3%Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6%","length":303,"tagName":"p"},{"type":"text","content":"SHANGHAI, March 30, 2026 /PRNewswire/ -- On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational efficiency of the CRO business. Throughout 2025, the Group's net profit was RMB269.3 million, representing a year-on-year increase of 21.3% compared with RMB220.0 million in the same period last year. Adjusted non-IFRS net profit increased from RMB314.6 million in the same period last year to RMB335.3 million, representing a year-on-year increase of approximately 6.6%, which was mainly due to the revenue growth of the CRO business, improved profitability arising from the optimization of Langhua Pharmaceutical's business mix, as well as investment income from the successful exit from incubation portfolio companies.","length":1211,"tagName":"p"},{"type":"image","alt":"VIVA Biotech logo (PRNewsfoto/Viva Biotech)","displaySize":"","headline":null,"caption":"VIVA Biotech logo (PRNewsfoto/Viva Biotech)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":88,"url":"https://media.zenfs.com/en/prnewswire.com/beb123bd4dbc2a29a9a21b4b33717401"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5FxKPBtSewoxq.081FGe1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1NQ--/https://media.zenfs.com/en/prnewswire.com/beb123bd4dbc2a29a9a21b4b33717401","width":400,"height":88}},"href":"https://mma.prnewswire.com/media/2934554/Viva_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Indust...